Spero Therapeutics, Inc. (SPRO): Price and Financial Metrics
GET POWR RATINGS... FREE!
SPRO POWR Grades
- Growth is the dimension where SPRO ranks best; there it ranks ahead of 93.99% of US stocks.
- SPRO's strongest trending metric is Stability; it's been moving up over the last 179 days.
- SPRO's current lowest rank is in the Momentum metric (where it is better than 4.72% of US stocks).
SPRO Stock Summary
- For SPRO, its debt to operating expenses ratio is greater than that reported by only 12.14% of US equities we're observing.
- Revenue growth over the past 12 months for SPERO THERAPEUTICS INC comes in at -49.41%, a number that bests only 4.23% of the US stocks we're tracking.
- SPERO THERAPEUTICS INC's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is 58.26%, greater than the shareholder yield of 96.83% of stocks in our set.
- If you're looking for stocks that are quantitatively similar to SPERO THERAPEUTICS INC, a group of peers worth examining would be NHWK, CIEN, SRDX, MX, and ACAD.
- Visit SPRO's SEC page to see the company's official filings. To visit the company's web site, go to sperotherapeutics.com.
SPRO Valuation Summary
- In comparison to the median Healthcare stock, SPRO's price/sales ratio is 321.05% higher, now standing at 8.
- SPRO's price/sales ratio has moved down 204.8 over the prior 65 months.
Below are key valuation metrics over time for SPRO.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| SPRO | 2023-03-17 | 8.0 | 2.2 | -0.7 | -0.3 |
| SPRO | 2023-03-16 | 8.6 | 2.3 | -0.7 | -0.3 |
| SPRO | 2023-03-15 | 8.6 | 2.3 | -0.7 | -0.3 |
| SPRO | 2023-03-14 | 8.7 | 2.4 | -0.7 | -0.3 |
| SPRO | 2023-03-13 | 8.5 | 2.3 | -0.7 | -0.3 |
| SPRO | 2023-03-10 | 8.7 | 2.4 | -0.7 | -0.3 |
SPRO's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- SPRO has a Quality Grade of C, ranking ahead of 28.84% of graded US stocks.
- SPRO's asset turnover comes in at 0.128 -- ranking 241st of 682 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows SPRO's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.128 | 1 | -1.651 |
| 2021-03-31 | 0.108 | 1 | -1.872 |
| 2020-12-31 | 0.072 | 1 | -2.390 |
| 2020-09-30 | 0.094 | 1 | -2.720 |
| 2020-06-30 | 0.110 | 1 | -2.104 |
| 2020-03-31 | 0.108 | 1 | -1.684 |
SPRO Price Target
For more insight on analysts targets of SPRO, see our SPRO price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $38.17 | Average Broker Recommendation | 1.58 (Moderate Buy) |
SPRO Stock Price Chart Interactive Chart >
SPRO Price/Volume Stats
| Current price | $1.36 | 52-week high | $9.00 |
| Prev. close | $1.40 | 52-week low | $0.68 |
| Day low | $1.35 | Volume | 606,200 |
| Day high | $1.46 | Avg. volume | 416,169 |
| 50-day MA | $1.70 | Dividend yield | N/A |
| 200-day MA | $1.46 | Market Cap | 47.69M |
Spero Therapeutics, Inc. (SPRO) Company Bio
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. It is developing SPR994, an oral carbapenem-class antibiotic for use in adults to treat MDR gram-negative infections; SPR741 that has completed Phase I clinical trial to treat MDR gram-negative infections in the hospital setting; SPR206, an agent that is in preclinical development stage to disrupt the outer membrane of gram-negative bacteria; and SPR720, an oral antibiotic that is in preclinical development stage for the treatment of pulmonary non-tuberculous mycobacterial infections. The company was founded in 2013 and is based in Cambridge, Massachusetts.
Latest SPRO News From Around the Web
Below are the latest news stories about SPERO THERAPEUTICS INC that investors may wish to consider to help them evaluate SPRO as an investment opportunity.
Spero Therapeutics Reschedules Fourth Quarter and Full Year 2022 Earnings Release and Conference Call to March 30, 2023CAMBRIDGE, Mass., March 13, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas, involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it has changed the date of its previously announced 2022 fourth quarter and full year earnings release and conference call from today, Monday, March 13, 2023 to |
Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2022 Financial Results on Monday, March 13, 2023CAMBRIDGE, Mass., March 06, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas, involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will host a conference call and live audio webcast on Monday, March 13, 2023 at 4:30 p.m. ET to report its fourth quarter and full year financial results and |
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)CAMBRIDGE, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that on February 22, 2023, the Compensation Committee of Spero’s Board of Directors approved the grant of an aggregate of 180,000 restricted stock unit awards (RSUs) t |
Spero Therapeutics to Present at Upcoming Investor ConferencesCAMBRIDGE, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Ankit Mahadevia, M.D., President and Chief Executive Officer of Spero Therapeutics, will present and be available for one-on-one meetings at the Cowen 43r |
Down -12.5% in 4 Weeks, Here's Why Spero Therapeutics, Inc. (SPRO) Looks Ripe for a TurnaroundSpero Therapeutics, Inc. (SPRO) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock. |
SPRO Price Returns
| 1-mo | -18.07% |
| 3-mo | -14.47% |
| 6-mo | -30.96% |
| 1-year | -83.89% |
| 3-year | -77.07% |
| 5-year | -90.11% |
| YTD | -21.39% |
| 2022 | -89.19% |
| 2021 | -17.43% |
| 2020 | 101.66% |
| 2019 | 56.34% |
| 2018 | -47.66% |
Continue Researching SPRO
Want to do more research on Spero Therapeutics Inc's stock and its price? Try the links below:Spero Therapeutics Inc (SPRO) Stock Price | Nasdaq
Spero Therapeutics Inc (SPRO) Stock Quote, History and News - Yahoo Finance
Spero Therapeutics Inc (SPRO) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...